Journal of Virology · 2011 · 30 citations · 30 references
Life SciencesImmunologyInfectious DiseasesAdaptive ImmunityImmunology Of Infectious DiseasesMolecular ImmunologyAntigen RecognitionCell-mediated ImmunityCellular Immunity In InfectionCytotoxic T Lymphocyte ResponsesT Cell ActivationT Cell BiologyAntigen Escape MutationsClinical ProgressionCompensatory MutationsCytotoxic T Lymphocyte EpitopesImmune Escape MutationsImmunological ResponseT-cell Immune ResponsesViral Escape Mutations
Molecular epidemiology studies have identified HLA-B 58:01 as a protective HIV allele. However, not all B 58:01-expressing persons exhibit slow HIV disease progression. We followed six HLA-B 58:01-positive, HIV subtype C-infected individuals for up to 31 months from the onset of infection and observed substantial variability in their clinical progression despite comparable total breadths of T cell responses. We therefore investigated additional immunological and virological factors that could explain their different disease trajectories. Cytotoxic T-lymphocyte (CTL) responses during acute infection predominantly targeted the TW10 and KF9 epitopes in p24(Gag) and Nef, respectively. Failure to target the TW10 epitope in one B 58:01-positive individual was associated with low CD4(+) counts and rapid disease progression. Among those targeting TW10, escape mutations arose within 2 to 15 weeks of infection. Rapid escape was associated with preexisting compensatory mutations in the transmitted viruses, which were present at a high frequency (69%) in the study population. At 1 year postinfection, B 58:01-positive individuals who targeted and developed escape mutations in the TW10 epitope (n = 5) retained significantly higher CD4(+) counts (P = 0.04), but not lower viral loads, than non-B 58:01-positive individuals (n = 17). The high population-level frequency of these compensatory mutations may be limiting the protective effect of the B 58:01 allele.
30
Julie Thompson, Desmond G. Higgins, Toby J. Gibson · Nucleic Acids Research · 1994 · 64.9K citations · Full text
<i>HLA</i>and HIV-1: Heterozygote Advantage and<i>B*35</i>-<i>Cw*04</i>Disadvantage
Mary Carrington, George W. Nelson, Maureen P. Martin et al. · Science · 1999 · 1.2K citations
Life Sciences, Genetics, Immunology +17
HIV evolution: CTL escape mutation and reversion after transmission
Alasdair Leslie, Katja Pfafferott, Polan Chetty et al. · Nature Medicine · 2004 · 853 citations